OmniComm Systems Signs Letter of Intent to Acquire Assets of Algorithm and its Algorics
OmniComm Systems, Inc. and Algorithm, Inc. have signed a letter of intent, under which OmniComm will acquire assets and assume liabilities of Algorics to build upon RBM and data analytics. By combining forces, the companies expect increased operating efficiency, strengthened traction in the risk-based approach solution area, new marketing opportunities, an expanded portfolio of electronic data capture solutions for the clinical trials industry, and will provide OmniComm with access to advanced analytics and algorithms.
Read the full release here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
